Literature DB >> 7706785

Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections.

J B Dale1, E C Chiang.   

Abstract

A fusion gene named LT-B-M5 was constructed encoding the entire B subunit of Escherichia coli labile toxin (LT-B), a 7 amino acid proline-rich linker, and 15 amino-terminal amino acids of type 5 streptococcal M protein. The purified LT-B-M5 was immunogenic in rabbits and evoked antibodies against a synthetic peptide copy of the amino-terminus of M5 (SM5[1-15]) and the native M5 protein and opsonic antibodies against type 5 streptococci. The hybrid protein retained the ganglioside-binding activity of LT-B and was tested in mice for its immunogenicity after local administration. Mice that were immunized intranasally with LT-B-M5 developed serum antibodies against SM5(1-15) and were significantly protected from death after intraperitoneal challenge infections with type 5 streptococci. The data show that protective systemic immune responses may be evoked after intranasal immunization with a fragment of M protein fused to LT-B.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706785     DOI: 10.1093/infdis/171.4.1038

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Immunogenicity of a 26-valent group A streptococcal vaccine.

Authors:  Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

3.  Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; E E Moran; T Larsen; W D Zollinger
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Molecular insight into invasive group A streptococcal disease.

Authors:  Jason N Cole; Timothy C Barnett; Victor Nizet; Mark J Walker
Journal:  Nat Rev Microbiol       Date:  2011-09-16       Impact factor: 60.633

5.  Immunogenicity of a divalent group A streptococcal vaccine.

Authors:  Yuexia Ding; Qiongqiong Ni; Jinlai Liu; Buyun Yu
Journal:  Rheumatol Int       Date:  2012-08-08       Impact factor: 2.631

Review 6.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

7.  Vaccine strategies to prevent rheumatic fever.

Authors:  E R Brandt; M F Good
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

8.  Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2.

Authors:  C Wortham; L Grinberg; D C Kaslow; D E Briles; L S McDaniel; A Lees; M Flora; C M Snapper; J J Mond
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

9.  Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii.

Authors:  S Ricci; D Medaglini; C M Rush; A Marcello; S Peppoloni; R Manganelli; G Palú; G Pozzi
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

10.  The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide.

Authors:  C D Partidos; M Pizza; R Rappuoli; M W Steward
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.